Published in Radiology on September 12, 2017
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med (2010) 13.82
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol (2013) 6.18
MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study. Lancet Neurol (2012) 5.91
Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. Lancet (2008) 5.63
Cachexia: a new definition. Clin Nutr (2008) 5.49
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med (2006) 5.20
Determining the longitudinal relaxation time (T1) of blood at 3.0 Tesla. Magn Reson Med (2004) 4.25
Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum Brain Mapp (2005) 4.11
Exercise program for nursing home residents with Alzheimer's disease: a 1-year randomized, controlled trial. J Am Geriatr Soc (2007) 4.05
PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med (2013) 4.02
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet (2008) 3.93
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet (2011) 3.76
MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol (2007) 3.47
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol (2009) 3.42
New ischaemic brain lesions on MRI after stenting or endarterectomy for symptomatic carotid stenosis: a substudy of the International Carotid Stenting Study (ICSS). Lancet Neurol (2010) 3.35
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol (2013) 3.23
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol (2011) 3.16
In vivo imaging of glucose uptake and metabolism in tumors. Nat Med (2013) 3.01
The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer (2008) 2.91
Amide proton transfer imaging of human brain tumors at 3T. Magn Reson Med (2006) 2.87
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol (2011) 2.75
Functional magnetic resonance imaging based on changes in vascular space occupancy. Magn Reson Med (2003) 2.68
Chronic cerebrospinal venous insufficiency and multiple sclerosis. Ann Neurol (2010) 2.63
Comparative overview of brain perfusion imaging techniques. Stroke (2005) 2.59
Small vessel disease and general cognitive function in nondisabled elderly: the LADIS study. Stroke (2005) 2.59
Coordination of voluntary and stimulus-driven attentional control in human cortex. Psychol Sci (2005) 2.57
Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. Stroke (2008) 2.57
Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology (2005) 2.47
Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry (2010) 2.44
MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". Lancet Neurol (2006) 2.44
Model-free arterial spin labeling quantification approach for perfusion MRI. Magn Reson Med (2006) 2.40
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain (2002) 2.30
Magnetic resonance imaging pattern recognition in hypomyelinating disorders. Brain (2010) 2.19
Control of object-based attention in human cortex. Cereb Cortex (2004) 2.16
Gas sensor array based on metal-decorated carbon nanotubes. J Phys Chem B (2006) 2.14
Loss of 'small-world' networks in Alzheimer's disease: graph analysis of FMRI resting-state functional connectivity. PLoS One (2010) 2.12
Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol (2005) 2.10
MRI in multiple sclerosis: current status and future prospects. Lancet Neurol (2008) 2.08
Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol (2005) 2.07
Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler (2011) 2.07
Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med (2007) 2.06
Neuroanatomy of hemispatial neglect and its functional components: a study using voxel-based lesion-symptom mapping. Brain (2009) 2.00
Acute lower respiratory tract infections in children: possible criteria for selection of patients for antibiotic therapy and hospital admission. 1984. Bull World Health Organ (2003) 1.99
Grey matter pathology in multiple sclerosis. Lancet Neurol (2008) 1.97
A microscale human liver platform that supports the hepatic stages of Plasmodium falciparum and vivax. Cell Host Microbe (2013) 1.95
Routine clinical brain MRI sequences for use at 3.0 Tesla. J Magn Reson Imaging (2005) 1.94
Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet (2004) 1.93
The QUASAR reproducibility study, Part II: Results from a multi-center Arterial Spin Labeling test-retest study. Neuroimage (2009) 1.92
Impact of white matter hyperintensities scoring method on correlations with clinical data: the LADIS study. Stroke (2006) 1.88
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol (2013) 1.84
Regional gray matter volume abnormalities in the at risk mental state. Biol Psychiatry (2006) 1.81
Precuneus atrophy in early-onset Alzheimer's disease: a morphometric structural MRI study. Neuroradiology (2007) 1.80
Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol (2011) 1.79
Imaging markers for Alzheimer disease: which vs how. Neurology (2013) 1.76
Unusual variants of Alexander's disease. Ann Neurol (2005) 1.76
On the etiology of incident brain lacunes: longitudinal observations from the LADIS study. Stroke (2008) 1.75
Policies, Political-Economy, and Swidden in Southeast Asia. Hum Ecol Interdiscip J (2009) 1.74
Sustained poststimulus elevation in cerebral oxygen utilization after vascular recovery. J Cereb Blood Flow Metab (2004) 1.72
Cerebral artery dilatation maintains cerebral oxygenation at extreme altitude and in acute hypoxia--an ultrasound and MRI study. J Cereb Blood Flow Metab (2011) 1.71
Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol (2012) 1.70
No association of abnormal cranial venous drainage with multiple sclerosis: a magnetic resonance venography and flow-quantification study. J Neurol Neurosurg Psychiatry (2010) 1.68
Improved detection of active multiple sclerosis lesions: 3D subtraction imaging. Radiology (2010) 1.68
Accelerated aging, decreased white matter integrity, and associated neuropsychological dysfunction 25 years after pediatric lymphoid malignancies. J Clin Oncol (2013) 1.67
Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol Aging (2008) 1.67
Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol (2002) 1.64
Microbleeds do not affect rate of cognitive decline in Alzheimer disease. Neurology (2012) 1.62
Overdiagnosis of multiple sclerosis and magnetic resonance imaging criteria. Ann Neurol (2005) 1.61
Is T2* enough to assess oxygenation? Quantitative blood oxygen level-dependent analysis in brain tumor. Radiology (2011) 1.60
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement (2011) 1.59
Model-free group analysis shows altered BOLD FMRI networks in dementia. Hum Brain Mapp (2009) 1.59
Overexpression, purification, and characterization of recombinant Ca-ATPase regulators for high-resolution solution and solid-state NMR studies. Protein Expr Purif (2003) 1.58
Patients with Alzheimer disease with multiple microbleeds: relation with cerebrospinal fluid biomarkers and cognition. Stroke (2009) 1.57
Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis. Neurology (2012) 1.57
Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. J Alzheimers Dis (2012) 1.57
A new leukoencephalopathy with brainstem and spinal cord involvement and high lactate. Ann Neurol (2003) 1.57
White matter tract integrity in aging and Alzheimer's disease. Hum Brain Mapp (2009) 1.57
Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients. Radiology (2008) 1.56
Resting-state fMRI changes in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging (2011) 1.54
Diffusion changes predict cognitive and functional outcome: the LADIS study. Ann Neurol (2013) 1.54
Continuous venovenous hemofiltration with or without extracorporeal membrane oxygenation in children. Pediatr Crit Care Med (2007) 1.54
Histopathologic correlates of radial stripes on MR images in lysosomal storage disorders. AJNR Am J Neuroradiol (2005) 1.53
Frontal-striatal dysfunction during planning in obsessive-compulsive disorder. Arch Gen Psychiatry (2005) 1.53
Risk of rapid global functional decline in elderly patients with severe cerebral age-related white matter changes: the LADIS study. Arch Intern Med (2007) 1.52
Quality-of-life valuations of advanced breast cancer by New Zealand women. Pharmacoeconomics (2006) 1.52
Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology (2013) 1.51
Identification of small molecules for human hepatocyte expansion and iPS differentiation. Nat Chem Biol (2013) 1.49
Acute Stroke Imaging Research Roadmap II. Stroke (2013) 1.47
Determinants of cerebral atrophy rate at the time of diagnosis of multiple sclerosis. Arch Neurol (2007) 1.47
The clinical profile of right temporal lobe atrophy. Brain (2009) 1.46
Noradrenaline mediates amygdala activation in men and women during encoding of emotional material. Neuroimage (2005) 1.45
Spatiotemporal distribution of white matter lesions in relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler (2012) 1.45
Flow territory mapping of the cerebral arteries with regional perfusion MRI. Stroke (2004) 1.41
Improved in vivo detection of cortical lesions in multiple sclerosis using double inversion recovery MR imaging at 3 Tesla. Eur Radiol (2010) 1.41
Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer (2011) 1.41
Radiologic patterns of necrosis after proton therapy of skull base tumors. Can J Neurol Sci (2013) 1.41
Suspected early dementia. BMJ (2011) 1.41